IRVINE, Calif. — December 7, 2022 — Immunis, Inc. Chairman, Dr. Hans Keirstead, presented at the 2022  Festival of Biologics Conference in Basel, Switzerland. The Festival of Biologics is a leading international event for drug discovery, development, manufacturing and marketing for clinical trials. Please enjoy these photos from the event.

About Festival of Biologics

The Festival of Biologics recruits experts in Big Pharma, biotech, academia and research to share novel data, create partnerships and bring new therapies to market. For additional information please visit: www.terrapinn.com/conference/festival-of-biologics/index.stm

About Immunis Inc.

Immunis is a private biotechnology company developing a novel immunomodulatory secretome product for the various manifestations of age and disease-related immune decline. The STEM product line leverages Immunis’ leading-edge capabilities in stem cell technologies to deliver a product of all natural, all human immune modulators in their natural relative physiological concentrations. For additional information about Immunis’ IMM01-STEM Phase 1/2a trial please visit: www.immunisbiomedical.com

Cautionary Note Regarding Forward-Looking Statements

This communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as applicable. Forward-looking statements include, but are not limited to, statements regarding our plans, beliefs, expectations and assumptions, as well as other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only as of the date as of which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on several assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions. This communication is neither an offer to sell nor a solicitation of an offer to buy any of the securities described herein.